Monday, January 14, 2013
Syncona Partners' first deal is an example of exactly
what The Wellcome Trust said its new venture fund would do - exploit its
freedom from traditional VC time horizons to invest in early stage companies.
The investment is an
undisclosed seed round in Cambridge Epigenetix Ltd., a diagnostics
spinout from the University of Cambridge. The newco will develop kits to
sequence and distinguish between methylated and hydroxymethylated base pairs at